Research information only, not medical advice. The only substantial clinical trial of ipamorelin tested it for postoperative gut motility, and that programme was discontinued. There is no controlled human evidence for the muscle or anti-ageing results it is marketed for; most data is preclinical.
Ipamorelin is a selective ghrelin-receptor agonist that raises growth hormone. Its most substantial human trial was a phase 2, double-blind, placebo-controlled study for postoperative ileus — a gut-motility use, not body composition — and that clinical programme was discontinued. For the fat-loss, muscle and anti-ageing results it is marketed for, there is no controlled human evidence; the rest of the data is animal or in-vitro. Research information, not medical advice.
For the full evidence base, clinical trials, and regulatory status, see the Ipamorelin research overview .
Sources
Frequently asked questions
- Does ipamorelin have real before and after results?
- Not from controlled human trials. Its one substantial clinical study was for postoperative gut motility and was discontinued; the muscle and anti-ageing uses are unproven.
- Is ipamorelin proven to build muscle?
- No controlled human trial has shown ipamorelin builds muscle. It raises growth hormone, but that has not been tested for body-composition outcomes in people.
Updated · sourced to primary documents